search
Back to results

Nasal Packing Following Endoscopic Endonasal Pituitary Resection

Primary Purpose

Pituitary Tumor

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
No nasal packing.
Nasal Packing
Sponsored by
Ottawa Hospital Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pituitary Tumor focused on measuring endoscopic, endonasal, transsphenoidal, surgical resection, pituitary tumour, nasal packing, Merocel

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years of age or older
  • undergoing endoscopic endonasal transsphenoidal approach to pituitary resection for pituitary tumors of any pathology for the first time

Exclusion Criteria:

  • patients who do not have a working understanding of English
  • patients with known allergy to Merocel nasal packing

Sites / Locations

  • The Ottawa HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Nasal Packing

No Nasal Packing

Arm Description

Nasal packing will be placed at the end of surgery.

No nasal packing will be placed during or after the surgery.

Outcomes

Primary Outcome Measures

Anterior Skull Basal Nasal Inventory-12 (ASK-12)
The ASK-12 is a validated patient reported nasal QOL questionnaire that evaluates morbidity after endonasal skull base surgery. Twelve symptoms related to nasal health are scored 0-5 and a global score is the mean value. Lower scores reflect better sinonasal quality of life.
Incidence of sinonasal adverse events
Evaluated by comparing the proportion of patients in each group who develop any sinonasal adverse events ( epistaxis, sinusitis, synechia, CSF rhinorrhea, nasal septal perforation

Secondary Outcome Measures

Change in EuroQual-5Dimension (EQ-5D)
Quality of Life Survey
Cost Analysis
An analysis of the direct and indirect costs related to hospitalization and medication use.
Change in Analgesic and Antibiotic Usage
The total amount (dosage) of analgesic and antibiotics administered during the study period.
Post operative pain
Will be captured using a visual analogue scale (VAS). Scores range from 0 to 10. Lower score indicate less severe pain.

Full Information

First Posted
July 6, 2018
Last Updated
March 21, 2023
Sponsor
Ottawa Hospital Research Institute
Collaborators
The Physicians' Services Incorporated Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT03677713
Brief Title
Nasal Packing Following Endoscopic Endonasal Pituitary Resection
Official Title
Nasal Packing Following Endoscopic Endonasal Pituitary Resection
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 20, 2019 (Actual)
Primary Completion Date
November 20, 2023 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ottawa Hospital Research Institute
Collaborators
The Physicians' Services Incorporated Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
There is considerable controversy about the use of nasal packing following endoscopic endonasal resection of pituitary tumors as a necessary treatment amongst Rhinology-Skull Base Surgeons. The justification for the routine use of nasal packing following pituitary surgery is not clear as this practice is not used for equally extensive sinus surgery. Further scientific evidence supporting this practice is lacking, and a recent survey of Canadian surgeons performing this surgery demonstrates clear division in practice for the routine use of nasal packing. Nasal packing causes patients significant discomfort requiring medication, and the use of packing adds direct and unintended hospitalization and health system costs for every case for which it is used. The benefits, short-comings, and associated costs of nasal packing following endoscopic endonasal transsphenoidal pituitary resection have not been studied. OBJECTIVE: To determine if nasal packing following endoscopic endonasal pituitary tumor surgery is a necessary treatment. The principal research questions for this study, our internal pilot of the RCT, pertain to feasibility of enrolment of patients undergoing endoscopic endonasal transsphenoidal pituitary tumor surgery using the full RCT protocol of nasal packing versus no nasal packing. The pilot will address feasibility of site-specific enrolment and feasibility of institutional ethics approval and protocol administration.
Detailed Description
BACKGROUND AND CLINICAL SIGNIFICANCE Over the past decade, the surgical method for removing pituitary tumors has shifted from a microscopic resection technique performed exclusively by a neurosurgeon, to an endoscopic resection done as a team with an otolaryngologist and neurosurgeon. This field continues to evolve given this recent shift in treatment technique. Nasal packing has historically been a post-operative intervention of treating the nose employed by otolaryngologists for any nasal surgery they performed. However, with the advent of endoscopic sinus surgery and changes in surgical technique, the use of nasal packing has become less common. A systematic review by Quinn et. Al (2013) showed that nasal packing caused more patient discomfort than any other post-septoplasty maneuver and did not prevent complications of septoplasty, but could contribute to adverse events following septoplasty. In North America, nasal packing is no longer commonly used after septoplasty. However, following the endoscopic resection of pituitary tumors, the practice of nasal packing is still widely employed. The reasoning for placement of nasal packing following surgery is not clear, just as it was not for its use following septoplasty. A thorough search of the literature did not identify any publications providing justification for the use of nasal packing. Published recommendations to reduce incidence of post-operative nasal complications after transsphenoidal pituitary tumor resection include use of specific nasal medications (intranasal corticosteroids) and regular nasal saline irrigation (in patients without cerebrospinal fluid rhinorrhea) to clear nasal mucosal hyperemia edema and secretions, as well as to prevent nasal synechiae and scarring, to maintain the sinus cavity drainage, and accelerate the recovery of the physiological function of the paranasal sinus. However, an evidence based recommendation in support or against routine nasal packing has not been made. A review from neurosurgical literature on perioperative management post transsphenoidal pituitary resection reports the majority of patients do not require insertion of nasal packing at the time of surgery, some patients (intraoperative Cerebral spinal fluid (CSF) leaks requiring sellar floor reconstruction, Cushing's Disease, and acromegaly) may benefit from their insertion, and if used packing is typically removed postoperative day 1. In January 2018 an informal email survey of Canadian Otolaryngologists who routinely perform endoscopic pituitary surgery with a neurosurgeon (total of 7 respondents out of 11 surgeons, 64% response rate) demonstrated that 5 of 7 use nasal packing following the procedure; 2 of 7 do not. Packing is usually left in place for 48 hours when used. A screening of institution websites (February 12, 2018) in North America where this surgery is routinely performed found a balanced number of institutions that list the use or non-use of nasal packing following endoscopic pituitary tumor resection (13 institutional websites screened, 8 institutions routinely use nasal packing, 5 do not). There is clinical equipoise related to the use of nasal packing. An objective study assessing the utility of nasal packing following endoscopic endonasal pituitary surgery has not yet been completed. This study seeks to answer the question, "Is routine nasal packing following endoscopic pituitary tumor surgery a necessary treatment?". The results of this trial have the potential to standardize practice patterns in Canada and internationally, and will inform evidence based practice while directly impacting the quality of care delivered to patients undergoing pituitary tumor resection. HYPOTHESIS Nasal packing following routine endoscopic pituitary tumor surgery is an unnecessary intervention that may cause patients unjustified post-operative discomfort, negatively affect their quality of life, and unnecessarily increase associated cost of care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pituitary Tumor
Keywords
endoscopic, endonasal, transsphenoidal, surgical resection, pituitary tumour, nasal packing, Merocel

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A single center, non-blinded, randomized controlled trial (RCT) will be conducted as a pilot study.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Nasal Packing
Arm Type
Active Comparator
Arm Description
Nasal packing will be placed at the end of surgery.
Arm Title
No Nasal Packing
Arm Type
Experimental
Arm Description
No nasal packing will be placed during or after the surgery.
Intervention Type
Procedure
Intervention Name(s)
No nasal packing.
Intervention Description
No nasal packing at the end of the surgery
Intervention Type
Procedure
Intervention Name(s)
Nasal Packing
Intervention Description
Patients will have nasal packing at the end of the surgery
Primary Outcome Measure Information:
Title
Anterior Skull Basal Nasal Inventory-12 (ASK-12)
Description
The ASK-12 is a validated patient reported nasal QOL questionnaire that evaluates morbidity after endonasal skull base surgery. Twelve symptoms related to nasal health are scored 0-5 and a global score is the mean value. Lower scores reflect better sinonasal quality of life.
Time Frame
Post Op Day 0, 1, 2, 3 and Post-Op weeks 2 and 4
Title
Incidence of sinonasal adverse events
Description
Evaluated by comparing the proportion of patients in each group who develop any sinonasal adverse events ( epistaxis, sinusitis, synechia, CSF rhinorrhea, nasal septal perforation
Time Frame
Post Op Day 0, 1, 2, 3 and Post-Op weeks 2 and 4
Secondary Outcome Measure Information:
Title
Change in EuroQual-5Dimension (EQ-5D)
Description
Quality of Life Survey
Time Frame
Post Op Day 0, 1, 2, 3 and Post-Op weeks 2 and 4
Title
Cost Analysis
Description
An analysis of the direct and indirect costs related to hospitalization and medication use.
Time Frame
Through study completion, 1 year.
Title
Change in Analgesic and Antibiotic Usage
Description
The total amount (dosage) of analgesic and antibiotics administered during the study period.
Time Frame
Post Op Day 0, 1, 2, 3 and Post-Op weeks 2 and 4
Title
Post operative pain
Description
Will be captured using a visual analogue scale (VAS). Scores range from 0 to 10. Lower score indicate less severe pain.
Time Frame
Post Op Day 0, 1, 2, 3 and Post-Op weeks 2 and 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age or older undergoing endoscopic endonasal transsphenoidal approach to pituitary resection for pituitary tumors of any pathology for the first time Exclusion Criteria: patients who do not have a working understanding of English patients with known allergy to Merocel nasal packing
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andrea L Lasso, M.Sc.
Phone
613-798-5555
Ext
10222
Email
alasso@toh.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Corliss Best, MD
Phone
613-737-8899
Ext
72968
Email
cbest@toh.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shaun Kilty, MD
Organizational Affiliation
The Ottawa Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Ottawa Hospital
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4E9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Lasso, MSc
Phone
6137985555
Ext
10222
Email
alasso@toh.ca

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Nasal Packing Following Endoscopic Endonasal Pituitary Resection

We'll reach out to this number within 24 hrs